| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Stephens initiated coverage on Cytek Biosciences Inc (NASDAQ:CTKB), a manufacturer and supplier of flow cytometry products and services.
Analysts Mason Carrico and Jacob Krahenbuhl view Cytek's full spectrum technology as differentiated and believe the performance advantages of its platforms are compelling to customers in higher-growth segments of the cell analysis market.
Stephens initiates with an Overweight rating and a price target of $9.
Cytek has continually surpassed the overall cell analysis market's growth, upholding a disciplined cost strategy and positioning itself as one of the few small-cap tool companies showing positive adjusted EBITDA. However, prevailing macroeconomic challenges dampen short-term growth, potentially leading to overestimated FY24 figures.
This skepticism appears to have factored into the stock's price to some extent, yet the shares remain relatively inexpensive based on revised projections. With an anticipated improvement in the macro environment, the analyst foresee a rebound in demand, driving accelerated revenue growth for Cytek. Consequently, this growth surge could lead to an expansion in CTKB's valuation multiples.
Cytek's Aurora and Northern Lights platforms are differentiated and address key limitations of conventional flow cytometers, analysts write.
Stephen writes that Cytek stands out with its superior instrument gross margins within the industry, setting it apart. Moving ahead, we anticipate sustained operating leverage. The company's primary focus remains on achieving profitable growth, yielding long-term rewards.
Price Action: CTKB shares are up 8.17% at $8.68 on the last check Thursday.
Photo via Company
Posted In: CTKB
